MCP-1 levels in the supernatant decreased in Treg-CM compared to OM, while MIP-1α levels were significantly higher in Treg-CM-treated BMSC supernatants compared to OM, Non-CM, and day 0 (Fig. 7d). The gene discussed is CCL2; the disease is ocular melanoma.